Radiopharm Theranostics Limited
RADX
$7.03
-$0.42-5.64%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.34M | 1.72M | 1.11M | 660.60K | 197.00K |
| Total Other Revenue | 5.66M | 2.36M | -887.50K | 93.90K | 1.07M |
| Total Revenue | 8.00M | 4.08M | 223.80K | 754.40K | 1.27M |
| Cost of Revenue | 20.13M | 17.18M | 14.33M | 14.30M | 14.15M |
| Gross Profit | -12.13M | -13.11M | -14.11M | -13.54M | -12.88M |
| SG&A Expenses | 10.67M | 10.15M | 9.68M | 10.01M | 10.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.80M | 27.33M | 24.02M | 24.31M | 24.43M |
| Operating Income | -22.80M | -23.25M | -23.79M | -23.55M | -23.16M |
| Income Before Tax | -24.77M | -26.40M | -28.14M | -29.83M | -31.38M |
| Income Tax Expenses | 68.10K | 88.90K | 109.60K | 86.90K | 63.30K |
| Earnings from Continuing Operations | -24.84 | -26.49 | -28.25 | -29.92 | -31.44 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 24.70K | -39.40K | -108.80K | -53.80K | -5.50K |
| Net Income | -24.81M | -26.53M | -28.36M | -29.97M | -31.45M |
| EBIT | -22.80M | -23.25M | -23.79M | -23.55M | -23.16M |
| EBITDA | -21.12M | -21.40M | -21.77M | -21.51M | -21.11M |
| EPS Basic | -0.01 | -0.03 | -0.04 | -0.06 | -0.08 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.02 | -0.03 | -0.04 |
| EPS Diluted | -0.01 | -0.03 | -0.04 | -0.06 | -0.08 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.02 | -0.03 | -0.04 |
| Average Basic Shares Outstanding | 8.32B | 6.44B | 4.56B | 3.05B | 1.55B |
| Average Diluted Shares Outstanding | 8.32B | 6.44B | 4.56B | 3.05B | 1.55B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |